

DP-008

## ASSESSMENT OF GENERIC MEDICINES DEVELOPMENT AND ENTRY DECISIONS BY THE MALAYSIAN GENERIC PHARMACEUTICAL INDUSTRIES

**Omotayo Fatokun<sup>1,2</sup>, Mohamed Izham Mohamed Ibrahim<sup>3</sup> and  
Mohamed Azmi Hassali<sup>1</sup>**

<sup>1</sup>School of Pharmaceutical Sciences, Universiti Sains Malaysia, Penang 11800, Malaysia;

<sup>2</sup>Faculty of Pharmaceutical Sciences, UCSI University, Kuala Lumpur 56000, Malaysia;

<sup>3</sup>College of Pharmacy, Qatar University, Doha, Qatar.

Email: tayofatokun@gmail.com

### ABSTRACT

The Malaysian government has in place policy and regulatory measures aimed at promoting generic medicines development and production.<sup>1</sup> This mechanism is in place mainly to ensure drug affordability and accessibility for the population. However, despite the cost-saving advantage of generic medicines, generic pharmaceutical industry consider several factors before taking decisions to develop and introduce a new generic drug into the market following patent expiration of innovator products. Therefore, this study assesses the factors determining decisions by Malaysian generic manufacturers to develop and introduce a generic version of an innovator product into the pharmaceutical market. Data was gathered by using a mail survey approach. The pre-validated questionnaire was mailed to members of the Malaysian Organization of Pharmaceutical Industries (MOPI). From the total mailing of 26 questionnaires, a total of 16 manufacturers responded to the survey (response rate of 61.5 %). Based on the mean score, market size of the innovator product before patent expiration had the highest and significant mean score (mean=4.15, SD=1.07,  $p=0.03$ ) and time to develop and obtain marketing approval for a new generic medicine had the lowest mean score (mean =3.23, SD=1.30,  $p=0.76$ ). Consistent with studies<sup>2,3</sup> in other countries, this present study revealed that pre-patent expiration market value of the innovator product is the major and significant factor Malaysian generic manufacturers consider before developing and introducing a new generic medicine into the market. Decision making process for the potential generic entrant is also attributed to the existence and strength of any barriers surrounding the entry process.

Reproduced with permission of copyright  
owner. Further reproduction prohibited  
without permission.